Navigation Links
FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
Date:10/21/2011

ResultsThe ARTEMIS study compared the efficacy and safety of PREZISTA/r 800/100 mg once daily (n=343) versus lopinavir/r 800/200 mg total daily dose (n=346) in treatment-naive adults with HIV-1. All patients received a fixed-dose combination of tenofovir and emtricitabine once daily. At 192 weeks, PREZISTA/r was shown to be non-inferior to lopinavir/r. This 192 week analysis showed that:

-- 70% of patients in the PREZISTA/r arm reached an undetectable viral load (less than 50 copies/m.) vs. 61% of patients in the lopinavir/r arm.  Virologic failure was 12% in the PREZISTA/r arm and 15% in the lopinavir/r arm. Statistical superiority of PREZISTA/r over the lopinavir/r regimen was demonstrated in both the intent-to-treat (ITT) and on-protocol (OP) analysis.

-- The most common treatment-related adverse reactions (greater or equal to 5 percent) of moderate intensity (greater or equal to grade 2) among patients in the PREZISTA/r arm vs. lopinavir/r arm were: diarrhea (9 percent vs. 16 percent); headache (7 percent vs. 6 percent); abdominal pain (6 percent vs. 6 percent); and rash (6 percent vs. 7 percent).

About the ARTEMIS StudyARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects) is an international, randomized, controlled, open-label, non-inferiority, Phase 3 trial that compared the efficacy and safety of PREZISTA/r versus lopinavir/r in treatment-naive HIV-1-infected adult patients with viral load greater than 5,000 copies/mL.

The main objective of the study was to demonstrate non-inferiority of PREZISTA/r versus lopinavir/r in the proportion of patients achieving virologic response, defined as confirmed HIV RNA less than 50 copies/mL. Non-inferiority of PREZISTA/r vs. lopinavir/r was defined as a maximum allowable difference of 12 percent for virologic response, with a one-sided significance level of alpha equal to 0.025.

Important Safety Information PREZISTA does not cure HIV-1 infection or AIDS, and
'/>"/>

SOURCE Janssen Therapeutics, Division of Janssen Products, LP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
2. FDA Approves Combination Therapy Juvisync
3. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
4. FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years
5. FDA Approves Soliris for Rare Pediatric Blood Disorder
6. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
7. FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
8. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
9. FDA Approves Adcetris to Treat Two Types of Lymphoma
10. FDA Approves the First Specific Treatment for Scorpion Stings
11. Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... announced today that it has acquired ... Inc. for $300 million. With the acquisition, Shire ... drops combining 0.6% povidone iodine (PVP-I) and 0.1% ... treatment of infectious conjunctivitis, an ocular surface condition ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... Calif., Jan. 4, 2011 Intarcia Therapeutics, Inc. today ... will present at the 29th Annual JP Morgan Healthcare ... 2011 at the Westin St. Francis Hotel in San ... About Intarcia Intarcia Therapeutics, ...
... Pa., Jan. 4, 2011 Owner and medical director of ... her practice and is now offering Pixel Perfect™ ... CO2 laser from Alma Lasers. "I,m very ... Cirillo-Hyland said. "As a long time provider of aesthetic laser ...
Cached Medicine Technology:Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference 2Philadelphia's Victoria A. Cirillo-Hyland, M.D. Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing and cooking food ... side at a young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. ... cookbook Recipes from My Persian Kitchen with the world. , Since Americans tend to ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... of it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive ... leaders from healthcare organizations with access to the tactics, techniques and practices required ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 9 article from USA Today ... according to the American Dental Association. According to a study by the American Dental ... million in a single year to 2.2 million a year. Dentists and ADA officials ...
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular ... IBAM NA’s cyclotron sites and research and development facilities. , “We are ... as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO ...
(Date:8/3/2015)... ... 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted to have an ... after many years of suffering and using medications with strong side effects. This had ... for extra time off or wait longer hours in the waiting rooms. Instead, he ...
Breaking Medicine News(10 mins):Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3
... rather than maintaining a stable weight may have an ... in the October 22 issue of Archives of Internal ... observed among women who did not take hormone therapy ... risk factor for developing breast cancer after menopause, according ...
... contribute to disease , , MONDAY, Oct. 22 (HealthDay News) -- Women ... more likely to develop breast cancer than women who maintain a ... when it comes to breast cancer, there,s no good time to ... gain throughout adulthood as well as weight gain at specific stages ...
... Greater ... Tucson Area, FT. LAUDERDALE, Fla., ... U.S., announces it is now,offering its industry-leading services in the greater Tucson, ... 111,expands its service in Arizona, which includes a location in Tempe as ...
... The Journal of the American Dental Association (JADA) ... publishing a global theme issue on poverty and ... worlds biomedical publications., The Council of Science Editors ... publication by science journals throughout the world of ...
... Ltd. (the,"Company") today announced the following with ... In late August of this year, we ... ("IntelliPharmaCeutics") had received,acceptance from the U.S. Food ... generic drug application (known as an ANDA) ...
... of Innovative Hypotheses, NEW YORK, Oct. 22 ... its 6th round of Novel Research,Grants-crucial funds to scientists ... why the lupus immune system so tragically attacks the,body ... national nonprofit,organization singularly devoted to pioneering innovative lupus research. ...
Cached Medicine News:Health News:Weight gain related to postmenopausal breast cancer risk 2Health News:Weight Gain Increases Breast Cancer Risk: Study 2Health News:Neptune Society Opens Tucson, Arizona Office 2Health News:Journal of the American Dental Association spotlights poverty 2Health News:IntelliPharmaCeuitics Ltd. Announces Generic Drug Commercialization Activities 2Health News:New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 2Health News:New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 3Health News:New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: